NautaDutilh assisted Merus N.V., a clinical-stage oncology company, in successfully raising approximately USD 173 million in gross proceeds through an underwritten public offering. All the shares in the offering were sold by Merus.
This involved 7,840,909 common shares (including the underwriter's option to purchase an additional 1,022,727 common shares), at a public offer price of USD 22.00 per share
Paul van der Bijl commented: "We are honored to have assisted Merus on this important transaction in their journey to clinically advance targeted treatments to address unmet needs of patients with various types of cancer. Merus is an inspiring company and a great team to work with."
Next to Paul, the team consisted of Nina Kielman, Joppe Schoute, Sabrina Legerstee, Charlotte Perrick, Mohamad Jabari and Sanne Mesu. Our team worked alongside the US team of Latham & Watkins.